PMID- 17945336
OWN - NLM
STAT- MEDLINE
DCOM- 20080115
LR  - 20220227
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Print)
IS  - 0090-8258 (Linking)
VI  - 108
IP  - 1
DP  - 2008 Jan
TI  - An exploratory analysis of HER-2 amplification and overexpression in advanced 
      endometrial carcinoma: a Gynecologic Oncology Group study.
PG  - 3-9
AB  - OBJECTIVES: To investigate the frequency and potential prognostic or predictive 
      value of HER-2 amplification or overexpression in advanced and recurrent 
      endometrial cancers. METHODS: Immunohistochemical staining (IHC; DAKO Herceptest) 
      and fluorescence in situ hybridization (FISH; Vysis Inc. PathVysion DNA Probe 
      Kit) were performed on specimens collected on a randomized Gynecologic Oncology 
      Group (GOG) protocol testing the addition of paclitaxel to doxorubicin/cisplatin. 
      RESULTS: HER-2 overexpression (either 2+ (moderate) or 3+ (strong) 
      immunostaining) and HER-2 gene amplification (a ratio of HER-2 copies to 
      chromosome 17 (CEP17) copies > or = 2) were detected in 44% (104 of 234; 58 were 
      2+ and 46 were 3+) and 12% (21 of 182) of specimens, respectively. There was a 
      significant increased frequency of overexpression in serous tumors vs. all others 
      (23 of 38, 61% vs. 81 of 196, 41%, respectively, P=0.03). HER-2 amplification 
      also appeared to be more common in serous tumors, but results were not 
      significant (6 of 28, 21% vs. 15 of 141, 11%, P=0.12). There was a significant 
      association between grade and HER-2 amplification among nonserous tumors, with 
      grades 1, 2, and 3 cancers demonstrating 3%, 2%, and 21% amplification, 
      respectively (P=0.003). Neither overexpression nor amplification predicted 
      overall survival (OS) after adjusting for treatment and performance status. 
      CONCLUSIONS: HER-2 amplification was more common in high grade tumors with a 
      trend to being more common in serous tumors. There was no clear evidence for a 
      survival difference or a difference in benefit from the addition of paclitaxel 
      for women with HER-2 amplified or overexpressed tumors; however, power to detect 
      clinically meaningful differences was low.
FAU - Grushko, T A
AU  - Grushko TA
AD  - University of Chicago Medical Center, Chicago, IL 60637, USA.
FAU - Filiaci, V L
AU  - Filiaci VL
FAU - Mundt, A J
AU  - Mundt AJ
FAU - Ridderstrale, K
AU  - Ridderstrale K
FAU - Olopade, O I
AU  - Olopade OI
FAU - Fleming, G F
AU  - Fleming GF
CN  - Gynecologic Oncology Group
LA  - eng
GR  - U10 CA027469-28/CA/NCI NIH HHS/United States
GR  - U10 CA037517-24/CA/NCI NIH HHS/United States
GR  - U10 CA037517/CA/NCI NIH HHS/United States
GR  - CA 37517/CA/NCI NIH HHS/United States
GR  - CA 27469/CA/NCI NIH HHS/United States
GR  - U10 CA027469/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20071018
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 80168379AG (Doxorubicin)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Cell Membrane/enzymology
MH  - Cisplatin/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Endometrial Neoplasms/drug therapy/*enzymology/genetics/pathology
MH  - Female
MH  - Gene Amplification
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/enzymology/genetics/pathology
MH  - Paclitaxel/administration & dosage
MH  - Receptor, ErbB-2/*biosynthesis/genetics
PMC - PMC2699629
MID - NIHMS38789
EDAT- 2007/10/20 09:00
MHDA- 2008/01/16 09:00
PMCR- 2009/06/22
CRDT- 2007/10/20 09:00
PHST- 2007/04/17 00:00 [received]
PHST- 2007/08/24 00:00 [revised]
PHST- 2007/09/04 00:00 [accepted]
PHST- 2007/10/20 09:00 [pubmed]
PHST- 2008/01/16 09:00 [medline]
PHST- 2007/10/20 09:00 [entrez]
PHST- 2009/06/22 00:00 [pmc-release]
AID - S0090-8258(07)00727-5 [pii]
AID - 10.1016/j.ygyno.2007.09.007 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2008 Jan;108(1):3-9. doi: 10.1016/j.ygyno.2007.09.007. Epub 2007 
      Oct 18.